BRISTOL-MYERS SQUIBB CO (BRM.DE) Fundamental Analysis & Valuation
FRA:BRM • US1101221083
Current stock price
49.61 EUR
+0.2 (+0.4%)
Last:
This BRM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BRM.DE Profitability Analysis
1.1 Basic Checks
- BRM had positive earnings in the past year.
- BRM had a positive operating cash flow in the past year.
- BRM had positive earnings in 4 of the past 5 years.
- In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of BRM (7.83%) is comparable to the rest of the industry.
- BRM's Return On Equity of 38.19% is amongst the best of the industry. BRM outperforms 92.16% of its industry peers.
- With an excellent Return On Invested Capital value of 19.52%, BRM belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
- BRM had an Average Return On Invested Capital over the past 3 years of 14.47%. This is in line with the industry average of 13.99%.
- The 3 year average ROIC (14.47%) for BRM is below the current ROIC(19.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROIC | 19.52% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
1.3 Margins
- With a decent Profit Margin value of 14.64%, BRM is doing good in the industry, outperforming 60.78% of the companies in the same industry.
- In the last couple of years the Profit Margin of BRM has grown nicely.
- BRM's Operating Margin of 35.82% is amongst the best of the industry. BRM outperforms 90.20% of its industry peers.
- In the last couple of years the Operating Margin of BRM has grown nicely.
- BRM has a Gross Margin (72.63%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. BRM.DE Health Analysis
2.1 Basic Checks
- BRM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for BRM has been increased compared to 1 year ago.
- The number of shares outstanding for BRM has been reduced compared to 5 years ago.
- BRM has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.51 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of BRM (2.51) is comparable to the rest of the industry.
- The Debt to FCF ratio of BRM is 3.51, which is a good value as it means it would take BRM, 3.51 years of fcf income to pay off all of its debts.
- BRM has a Debt to FCF ratio of 3.51. This is in the better half of the industry: BRM outperforms 62.75% of its industry peers.
- BRM has a Debt/Equity ratio of 2.33. This is a high value indicating a heavy dependency on external financing.
- BRM has a worse Debt to Equity ratio (2.33) than 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Altman-Z | 2.51 |
ROIC/WACC2.26
WACC8.65%
2.3 Liquidity
- A Current Ratio of 1.26 indicates that BRM should not have too much problems paying its short term obligations.
- BRM has a Current ratio of 1.26. This is comparable to the rest of the industry: BRM outperforms 47.06% of its industry peers.
- BRM has a Quick Ratio of 1.14. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- BRM's Quick ratio of 1.14 is fine compared to the rest of the industry. BRM outperforms 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 |
3. BRM.DE Growth Analysis
3.1 Past
- BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
- BRM shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
- Looking at the last year, BRM shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
- Measured over the past years, BRM shows a small growth in Revenue. The Revenue has been growing by 2.54% on average per year.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- BRM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.15% yearly.
- The Revenue is expected to decrease by -5.54% on average over the next years.
EPS Next Y2.96%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
EPS Next 5Y-4.15%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BRM.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 9.52, which indicates a very decent valuation of BRM.
- Based on the Price/Earnings ratio, BRM is valued cheaper than 90.20% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.33), we can say BRM is valued rather cheaply.
- BRM is valuated reasonably with a Price/Forward Earnings ratio of 9.24.
- 90.20% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
- BRM is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.16, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.52 | ||
| Fwd PE | 9.24 |
4.2 Price Multiples
- BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 92.16% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 90.20% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.3 | ||
| EV/EBITDA | 7.2 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of BRM may justify a higher PE ratio.
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -4.23% in the coming years.
PEG (NY)3.22
PEG (5Y)N/A
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
5. BRM.DE Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 4.24%, BRM is a good candidate for dividend investing.
- BRM's Dividend Yield is rather good when compared to the industry average which is at 1.95. BRM pays more dividend than 82.35% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
5.2 History
- The dividend of BRM is nicely growing with an annual growth rate of 6.51%!
Dividend Growth(5Y)6.51%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 71.52% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
- BRM's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
BRM.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BRM (4/14/2026, 7:00:00 PM)
49.61
+0.2 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners83.83%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap101.29B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target53.51 (7.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
Yearly Dividend2.14
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)2.11%
PT rev (3m)13.45%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)0.42%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)4.46%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)6.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.52 | ||
| Fwd PE | 9.24 | ||
| P/S | 2.48 | ||
| P/FCF | 9.3 | ||
| P/OCF | 8.44 | ||
| P/B | 6.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.2 |
EPS(TTM)5.21
EY10.5%
EPS(NY)5.37
Fwd EY10.82%
FCF(TTM)5.33
FCFY10.75%
OCF(TTM)5.88
OCFY11.85%
SpS20.02
BVpS7.67
TBVpS-9.3
PEG (NY)3.22
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROCE | 25.91% | ||
| ROIC | 19.52% | ||
| ROICexc | 23.22% | ||
| ROICexgc | 84.94% | ||
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% | ||
| FCFM | 26.65% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 32.69% | ||
| Cap/Sales | 2.72% | ||
| Interest Coverage | 8.22 | ||
| Cash Conversion | 66.54% | ||
| Profit Quality | 182.1% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.51 |
F-Score7
WACC8.65%
ROIC/WACC2.26
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.96%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.85%
Revenue Next 2Y-1.95%
Revenue Next 3Y-5.42%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.35%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%
BRISTOL-MYERS SQUIBB CO / BRM.DE Fundamental Analysis FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for BRM stock?
The Price/Earnings (PE) ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 9.52 and the Price/Book (PB) ratio is 6.47.
Can you provide the financial health for BRM stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.